

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CD5 Antibody, anti-human, PE-Vio® 770, REAfinity™

RRID:AB_2658600

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-111-109, RRID:AB_2658600

Antibody Information

URL: http://antibodyregistry.org/AB_2658600

Proper Citation: Miltenyi Biotec Cat# 130-111-109, RRID:AB_2658600

Target Antigen: CD5

Host Organism: human

Clonality: monoclonal

Comments: Applications: MACS Flow Cytometry
Antigen Distribution: B cells, lymphocytes, T cells, thymocytes

Antibody Name: CD5 Antibody, anti-human, PE-Vio® 770, REAfinity™

Description: This monoclonal targets CD5

Target Organism: human

Clone ID: clone REA782

Antibody ID: AB_2658600

Vendor: Miltenyi Biotec

Catalog Number: 130-111-109

Record Creation Time: 20231110T034411+0000

Record Last Update: 20260901T014725+0000

Ratings and Alerts

No rating or validation information has been found for CD5 Antibody, anti-human, PE-Vio® 770, REAfinity™.

No alerts have been found for CD5 Antibody, anti-human, PE-Vio® 770, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jung HS, et al. (2023) SOX18-enforced expression diverts hemogenic endothelium-derived progenitors from T towards NK lymphoid pathways. iScience, 26(5), 106621.

Jung HS, et al. (2021) SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. Cell reports, 34(7), 108758.